A class action lawsuit has been filed against Fractyl Health, accusing the company of misleading investors about the effectiveness of its Revita DMR System for treating type 2 diabetes and obesity. The complaint alleges that Fractyl overstated the therapy's efficacy and failed to disclose operational issues affecting clinical trial results. Following disappointing six-month data released in January 2026, Fractyl's stock price plummeted over 68%, with further declines after a Morgan Stanley downgrade. Investors who bought shares between January 2025 and January 2026 may join the lawsuit, with a lead plaintiff deadline set for October 20, 2026.
Bunzl PLC reported stronger-than-expected financial results with an EPS of $0.60, surpassing the $0.56 consensus. Revenue reached $8.04 billion, driven by a 3.2% underlying growth, especially in North America. The operating margin improved to 7.3%, p...
Palo Alto Networks is set to report strong earnings per share (EPS) of $0.98 and revenue of $3.35 billion for the upcoming quarter, reflecting significant growth from last year. Investor optimism is driven by robust cybersecurity sector trends and a ...
Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...
Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...
Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...
